Hypha Discovery is a microbial biotechnology company helping partners in pharmaceutical and agrochemical R&D succeed through the discovery and production of microbial and mammalian metabolites. We are experts in the scalable production of drug metabolites and oxidised derivatives of lead compounds, and possess a wealth of experience in the discovery, isolation and structure elucidation of microbial natural products.
NEW PolyCYPs® biocatalysis kits
Hypha’s PolyCYPs® kits provide a fast and easy way to access CYP-derived drug metabolites and derivatives formed by oxidation at aliphatic or aromatic moieties at susceptible positions. Download a pdf of the PolyCYPs brochure.
Click here to find out more about PolyCYPs kits
NEWS & EVENTS
Come and meet us at the following events
Annual One-Day Meeting on Medicinal Chemistry
23rd November, Namur, Belgium
– Liam will be presenting a poster –
Let us know if you would like a copy of a new paper published in Xenobiotica entitled Microbial Biotransformation – An Important Tool for the Study of Drug Metabolism, which describes some interesting projects Hypha have undertaken for Merck and Janssen with several difficult-to-synthesize hydroxylated and glucuronidated metabolites. Read the abstract at http://bit.ly/2xb6H9d
Download a copy of our brochure on drug metabolites and C-H activated derivatives
Our brochure on drug metabolites and C-H activated derivatives is now available. Inside we feature interesting case studies and client projects, including the following topics:
- Phase l CYP and non-CYP metabolites
- Phase ll conjugated metabolites
- Isotopically labelled metabolites
- Lead diversification and late stage functionalization
- Polar / C-H activated derivatives
In our latest newsletter we look at superior drug derivatives via late stage hydroxylation. Biocatalytic late stage functionalization has become a useful tool in order to rapidly access and explore compounds with superior properties compared to the original drug candidate, either resulting in improved potency and/or increased metabolic stability.
Superior drug leads via late stage hydroxylation